Sentences with phrase «breast tumor response»

Not exact matches

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

The resulting «map» of gene - drug interactions allowed the researchers to accurately predict the responses of multiple human cancer cell lines to different chemotherapy agents based on the cell lines» genetic profiles and also revealed new genetic factors that appear to determine the response of breast and ovarian tumor cells to common classes of chemotherapy treatment.

The findings could lead to future investigation into potential new ways to treat and monitor breast cancer by looking outside the tumor and exploiting the patient's systemic immune system response.

Overall, the pathologic complete response rate was lower among women with at least one PIK3CA mutation in their tumor compared with women without a PIK3CA mutation, but the effect was only significant among the group of women with HER2 - and hormone receptor - positive breast cancer.

Platinum - based therapies are being tested in clinical trials for triple - negative breast cancer, and evaluation of tumor - infiltrating lymphocytes is an important factor in determining response to this treatment.

In nonmetastatic triple - negative breast cancer (TNBC) patients, we investigated whether circulating tumor DNA (ctDNA) detection can reflect the tumor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery.

The researchers tested whether stromal tumor infiltrating lymphocytes (TILs) and other immune cells might predict responses to therapy in a set of 30 HER2 - positive breast cancer tissues treated with TCHP (26 patients) or with TCH without pertuzumab (4 patients).

Inclusion Criteria: • Availability of tumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion critumor tissue for mesothelin expression testing • Histologically - confirmed, mesothelin - expressing metastatic or advanced non-metastatic disease (tumour type specific inclusion criteria) • At least one measurable lesion according to either Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or International Thymic Malignancy Interest Group (ITMIG) modified RECIST 1.1 as applicable • Adequate bone marrow, liver, renal and coagulation function • Left ventricular ejection fraction (LVEF) ≥ 50 % of the lower limit of normal (LLN) according to local institutional ranges • Eastern Cooperative Oncology Group (ECOG) 0 or 1 Exclusion Criteria: • More than one prior anti - tubulin / microtubule agent • Corneal epitheliopathy or any eye disorder that may predispose the patients to this condition • Symptomatic Central nervous system (CNS) metastases and / or carcinomatous meningitis • Contraindication to both CT and MRI contrast agents • Active hepatitis B or C infection • Pregnant or breast - feeding patients • Tumor type specific exclusion criTumor type specific exclusion criteria

: This study evaluated the effects of an antagonistic analog of growth hormone - releasing hormone, MIA - 602, on tumor growth, response to doxorubicin, expression of drug resistance genes, and efflux pump function in human triple negative breast cancers.

Introduction: This study evaluated the effects of an antagonistic analog of growth hormone - releasing hormone, MIA - 602, on tumor growth, response to doxorubicin, expression of drug resistance genes, and efflux pump function in human triple negative breast cancers.

In his project, Dr. Li is investigating whether beta blockers target T cells to control breast tumor development, and is also working to understand how this pathway regulates T cell responses to tumors, which may reveal novel targets for the immunotherapy of breast cancer.

This is supported by recently published data in the New England Journal of Medicine (21), where patients with triple - negative breast cancer were seen to show increased complete pathologic response to bevacizumab treatment, with no detectable tumor at primary or metastatic sites, whereas no improvement was observed in hormone receptor — positive cases.

Title: The immune microenvironment in hormone receptor - positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab Date / Time: Tuesday, April 17 2018, 1:00 pm - 5:00 pm CT Author: A. Waks et al, Dana Farber Cancer Institute Poster # / Location: 4565 / Section 26, Board 1 Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7859 HR + / HER2 - breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevacizumab.